Kadant, Prudential Financial, Bristol-Myers Squibb, and MMM were noted on July 2, 2025, as high-growth/large-cap stocks under market scrutiny.
1 report, 0 independent
Updated Jul 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kadant, Prudential Financial, Bristol-Myers Squibb, and MMM were noted on July 2, 2025, as high-growth/large-cap stocks under market scrutiny.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Prudential plc
British multinational life insurance and financial services company
-
Kadant
US-based paper company
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
-
MMM
Russian company that perpetrated one of the world's largest Ponzi schemes of all time
Nothing else this week.
Related events
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- MarketBeat reported consensus analyst targets and compared financial health for Bristol-Myers Squibb and Shionogi & Co., Ltd.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
Coverage
Newest first; wire copies grouped- Unknown outlet